Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 2/20 | 0.51 |
| ▸ | GNAI3 | P08754 | 3/20 | 0.50 |
| ▸ | GNAO1 | P09471 | 3/20 | 0.50 |
| ▸ | GNAI1 | P63096 | 3/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.44 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9661728 | 0.98 | S1PR1 (0.54) | S1PR1GNAI3GNAO1GNAI1KCNH2 | |
| SCHEMBL5543885 | 0.98 | S1PR1 (0.54) | S1PR1GNAI3GNAO1GNAI1KCNH2 | |
| SCHEMBL5548993 | 0.98 | S1PR1 (0.54) | S1PR1GNAI3GNAO1GNAI1KCNH2 | |
| SCHEMBL14330061 | 0.98 | S1PR1 (0.54) | S1PR1GNAI3GNAO1GNAI1KCNH2 | |
| SCHEMBL23105622 | 0.94 | S1PR1 (0.49) | S1PR1GNAI3GNAO1GNAI1KCNH2 | |
| SCHEMBL10060138 | 0.85 | HSD17B10 (0.48) | S1PR1HSD17B10CYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL15499754 | 0.85 | HSD17B10 (0.48) | S1PR1HSD17B10CYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL15499048 | 0.85 | HSD17B10 (0.48) | S1PR1HSD17B10CYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL9644791 | 0.85 | HSD17B10 (0.52) | S1PR1HSD17B10PAOXCYP1A2MAPK1 | |
| SCHEMBL10826413 | 0.82 | GNAI3 (0.53) | S1PR1GNAI3GNAO1GNAI1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7071195-B2 | Amine and amide derivatives as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2006-07-04 | — | — | US | disclosed |
| US-20060052388-A1 | Amine and amide derivatives as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders | DAX SCOTT L | 2006-03-09 | — | — | US | disclosed |
| US-6987188-B2 | 3a,4,5,9b-tetrahydro-1H-benz[e]indol-2-yl amine-derived neuropeptideYreceptors ligands useful in the treatment of obesity and other disorders | DAX SCOTT | 2006-01-17 | — | — | US | disclosed |
| EP-1202986-B1 | AMINE AND AMIDE DERIVATIVES AS LIGANDS FOR THE NEUROPEPTIDE Y Y5 RECEPTOR USEFUL IN THE TREATMENT OF OBESITY AND OTHER DISORDERS | ORTHO MCNEIL PHARM INC (US) | 2005-10-12 | — | — | EP | disclosed |
| US-20050054709-A1 | 3a,4,5,9b-tetrahydro-1H-benz[e]indol-2-yl amine-derived neuropeptideYreceptors ligands useful in the treatment of obesity and other disorders | DAX SCOTT (US) | 2005-03-10 | — | — | US | disclosed |
| US-6841552-B1 | 3a,4,5,9b-tetrahydro-1H-benz[e]indol-2-yl amine-derived neuropeptide Y receptors ligands useful in the treatment of obesity and other disorders | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2005-01-11 | — | — | US | disclosed |
| EP-1493742-A1 | Amine and amide derivatives as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders | Ortho-Mcneil Pharmaceutical, Inc. (US) | 2005-01-05 | — | — | EP | disclosed |
| US-20020115715-A1 | Amine and amide derivatives as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders | DAX SCOTT L (US) | 2002-08-22 | — | — | US | disclosed |
| EP-1202986-A1 | AMINE AND AMIDE DERIVATIVES AS LIGANDS FOR THE NEUROPEPTIDE Y Y5 RECEPTOR USEFUL IN THE TREATMENT OF OBESITY AND OTHER DISORDERS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2002-05-08 | — | — | EP | disclosed |
| US-6380224-B1 | FOR THERAPY OF EATING DISORDERS, OBESITY, BULIMIA NERVOSA, DIABETES, MEMORY LOSS, EPILEPTIC SEIZURES, MIGRAINE, SLEEP DISTURBANCES, PAIN, SEXUAL/REPRODUCTIVE DISORDERS, DEPRESSION AND ANXIETY | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-04-30 | — | — | US | disclosed |
| EP-1177172-A1 | 3a,4,5,9b-TETRAHYDRO-1H-BENZ e]INDOL-2-YL AMINE-DERIVED NEUROPEPTIDE Y RECEPTORS LIGANDS USEFUL IN THE TREATMENT OF OBESITY AND OTHER DISORDERS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2002-02-06 | — | — | EP | disclosed |
| WO-2001009120-A1 | AMINE AND AMIDE DERIVATIVES AS LIGANDS FOR THE NEUROPEPTIDE Y Y5 RECEPTOR USEFUL IN THE TREATMENT OF OBESITY AND OTHER DISORDERS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2001-02-08 | — | — | WO | disclosed |
| WO-2000068197-A1 | 3a,4,5,9b-TETRAHYDRO-1H-BENZ[e]INDOL-2-YL AMINE-DERIVED NEUROPEPTIDE Y RECEPTORS LIGANDS USEFUL IN THE TREATMENT OF OBESITY AND OTHER DISORDERS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2000-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052388-A1 | Amine and amide derivatives as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders | NPY5R, NPY1R, NPY2R | S1PR1 800/4885GNAI3 1586/4885GNAO1 628/4885 |
| US-20050054709-A1 | 3a,4,5,9b-tetrahydro-1H-benz[e]indol-2-yl amine-derived neuropeptideYreceptors ligands useful in the treatment of obesity and other disorders | NPY1R, NPY4R, NPY2R | S1PR1 585/4885GNAI3 1036/4885GNAO1 1046/4885 |
| US-20020115715-A1 | Amine and amide derivatives as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders | NPY5R, NPY1R, NPY2R | S1PR1 747/4885GNAI3 1565/4885GNAO1 590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.